COGNITION THERAPEUTICS INC (CGTX) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for COGNITION THERAPEUTICS INC?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, COGNITION THERAPEUTICS INC's filing signal continuing positive.
earningsVibe SuperAnalyst™ Verdict: CONTINUING POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does COGNITION THERAPEUTICS INC actually do?
Answer:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Its lead product candidate, zervimesine (CT1812), is designed to protect neuronal synapses by preventing the binding of pathogenic protein oligomers, such as beta-amyloid and alpha-synuclein, which are implicated in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The company is advancing zervimesine through clinical trials for AD and DLB, supported by significant grant funding from the National Institute on Aging. Cognition Therapeutics also explores other therapeutic candidates derived from its proprietary screening techniques.
Question:
What are COGNITION THERAPEUTICS INC's revenue drivers?
Answer:
The company has not yet generated revenue from product sales and expects to finance its operations through equity offerings, debt financings, collaborations, and licensing arrangements until it can commercialize its product candidates.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required